XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
CEO: Allen Warren Davidoff. Company website
XORTX Therapeutics Inc. (XRTX) trades at $2.07, up 24.40% on the day, as of Sep 20, 2026 15:00 UTC.
XORTX Therapeutics Inc. has a market capitalisation of $575,079.79, calculated from the live XRTX share price and shares outstanding.
XRTX has no meaningful price-to-earnings ratio: XORTX Therapeutics Inc. lost $16.00 per share over the last twelve months, and a P/E is only defined on positive earnings.
XORTX Therapeutics Inc. generated revenue of $0.00 over the trailing twelve months.
XRTX has traded between $1.59 and $3.60 over the past 52 weeks, and the last price is 42.6% below that high.
Yes. XORTX Therapeutics Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
XORTX Therapeutics Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in CA .
Allen Warren Davidoff is the chief executive of XORTX Therapeutics Inc., which employs 2 people.
QFI Terminal shows XRTX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open XRTX in Terminal See plans